Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia

References

• Olszewski W, Gluszek J. Vasopressin antagonists in treatment of hyponatremia. Pol. Arch. Med. Wewn.8, 356–362 (2007).
   Google Scholar
• Gross P. Treatment of hyponatremia. Intern. Med.47, 885–891 (2008).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Hamad B, Yasothan U, Kirkpatrick P. Tolvaptan. Nat. Rev.8, 611–612 (1994).
   Google Scholar
• Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355, 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet371, 1624–1632 (2008).
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am. J. Med.120, S1–S21 (2007).
   Google Scholar
• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am. J. Med.119, S30–S35 (2006).
   PubMed Web of Science ®Google Scholar
• Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am. J. Med.119, S79–S82 (2006).
   PubMed Web of Science ®Google Scholar
• Boyer TD. Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology51, 699–702 (2010).
   Google Scholar
• Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V2 receptor antagonist pharmacology and clinical trials. Cardiovasc. Drug Rev.25, 1–13 (2007).
   PubMedGoogle Scholar
• Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol.47, 1498–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Hauptman PJ, Zimmer C, Udelson J et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol.46, 609–614 (2005).
   PubMed Web of Science ®Google Scholar
• Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation118, 410–421 (2008).
   PubMed Web of Science ®Google Scholar
• Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist and furosemide or hydrochlorothiazide. J. Cardiovasc. Pharmacol.50, 213–222 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure, a randomized controlled trial. JAMA291, 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA297, 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J.146, 9–18 (2003).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure, the EVEREST outcome trial. JAMA297, 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J. Am. Coll. Cardiol.49, 2151–2159 (2007).
   PubMed Web of Science ®Google Scholar
• Vaprisol (conivaptan hydrochloride injection). Prescribing Information. Astellas Pharma, IL, USA, October 2008.
   Google Scholar
• SAMSCA (tolvaptan). Prescribing Information. Otsuka America Pharmaceutical Inc., MD, USA, May 2009.
   Google Scholar
• Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol.290, 273–278 (2006).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind randomized trial. Circulation107, 2690–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gottlieb SS, Udelson JE et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol.97, 1064–1067 (2006).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J. Am. Cardiol.52, 1540–1545 (2008).
   Google Scholar
• Berl T, Quittnat-Pelletier F, Verbalis JG et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol.21, 705–712 (2010).
   PubMed Web of Science ®Google Scholar
• Adrogué HJ. Consequences of inadequate management of hyponatremia. Am. J. Nephrol.25, 240–249 (2005).
   PubMed Web of Science ®Google Scholar
• Fleming KM, Aithal GP, Solaymani-Dodaran M et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001; a general population based study. J. Hepatol.49, 732–738 (2008).
   PubMed Web of Science ®Google Scholar
• Wang X, Gattone V, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol.16, 846–851 (2005).
   PubMed Web of Science ®Google Scholar